ScreenerHero

INKTMiNK Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · minktherapeutics.com
12.20USD+9.61%Mkt Cap: 62.26M $P/E: —

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell ther…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap62.26M $
Enterprise Value50.49M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.49M $
Revenue/Share—
Last Price12.20 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.39
PEG—
EV/EBITDA-4.08
EV/Revenue—
P/S—
P/B-4.22
EPS (TTM)-2.37
EPS (Forward)-2.65
52W Range
8.48044% of range16.98
52W High16.98 USD
52W Low8.480 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE87.82%
ROA-87.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.93M $
CapEx (TTM)—
FCF Margin—
FCF Yield-8.43%
Net Debt-8.81M $
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity-0.36
Current Ratio1.23
Quick Ratio1.16
Book Value/Sh-2.7520 USD
Cash/Share1.726 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 28, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)+219.7%
Target Range35.00 USD – 43.00 USD
$35.00+219.7% to mean$43.00
# Analysts2
Ownership
Shares Out.5.10M
Float2.00M
Insiders59.23%
Institutions4.01%
Short Interest
Short Ratio7.8d
Short % Float3.87%
Short % Out.1.89%
Shares Short94.09K
Short (prev mo.)112.46K
Technical
SMA 5011.31 (+7.9%)
SMA 20011.46 (+6.5%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)10.65K
Avg Vol (10d)8.00K
Technical Indicators
RSI (14)62.2
MACD0.1022
MACD Signal-0.0163
MACD Hist.+0.1184
BB Upper11.90 USD
BB Middle10.99 USD
BB Lower10.08 USD
BB Width16.60%
ATR (14)0.5964 USD
Vol Ratio (20d)1.34x